
3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, Wall Street offers no shortage of ways for investors to grow their wealth. But among this vast sea of pathways to become richer is one of the most-successful strategies: buying and holding high-quality dividend stocks.
Companies that pay a regular dividend often share a few traits:
They're usually profitable on a recurring basis.
They're often capable of providing transparent long-term growth outlooks.
They've demonstrated to Wall Street they can successfully navigate their way through recessions.
More importantly, dividend stocks have a knack for outperforming. In The Power of Dividends: Past, Present, and Future, researchers at Hartford Funds, in collaboration with Ned Davis Research, found that dividend stocks averaged an annualized return of 9.17% from 1973 through 2023, and did so while being 6% less volatile than the broad-based S&P 500. Meanwhile, the non-payers delivered a more modest annualized return of 4.27% over the same half century, and were 18% more volatile than the benchmark S&P 500.
Ideally, investors want the highest yield possible with the least amount of risk. The issue is that risk and yield tend to correlate, which means a lot of vetting is necessary on the part of investors to avoid getting stuck in a yield trap.
The good news is there are three exceptionally well-known, ultra-high-yield dividend stocks -- sporting an average yield of 6.65% -- which can be bought with confidence right now by patient investors with $300.
Pfizer: 6.74% yield
The first brand-name stock that long-term income seekers can set and forget in their portfolios is pharmaceutical goliath Pfizer (NYSE: PFE), whose 6.74% yield is nearing an all-time high.
Although Pfizer's stock chart gives the perception that it's struggling, a deeper dive into the company's operating performance shows it's been a victim of its own success. After generating in excess of $56 billion in sales from its COVID-19 therapies in 2022, Pfizer's combined COVID-19 drug sales fell to a little over $11 billion in 2024.
But taking a wider-lens approach completely changes the perspective of this data. Although COVID-19 sales declined by around $45 billion over the last two years, any revenue generated from Pfizer's COVID-19 vaccine (Comirnaty) and oral therapy (Paxlovid) compares quite favorably with the $0 it was generating from this segment four years ago. Between 2020 and 2024, Pfizer's net sales soared 52% to $63.6 billion. That's not a struggling business.
Something else exciting is Pfizer's $43 billion acquisition of cancer-drug developer Seagen in December 2023. This deal vastly expands Pfizer's oncology pipeline and provides an immediate boost to its sales. It'll also result in significant cost savings, which are reflected in its 2025 profit forecast.
Pfizer benefits from healthcare being a highly defensive industry, as well. Since we don't get to choose when we become ill or what ailment(s) we develop, the company's operating cash flow tends to be predictable and consistent. This makes its forward price-to-earnings (P/E) ratio of 8 quite the bargain.
Verizon Communications: 6.69% yield
A second brand-name stock that can be confidently scooped up with $300 by opportunistic long-term investors is telecom stalwart Verizon Communications (NYSE: VZ). Verizon's nearly 6.7% yield is also approaching an all-time high.
If there's a knock against Verizon, it's that it's not an artificial intelligence (AI) stock. Investors are gravitating to high-growth, high-volatility tech stocks, and not mature businesses like Verizon that generate low-single-digit sales growth and highly predictable cash flow. But investor apathy toward this telecom giant can be income seekers' gain.
The beauty of wireless services and the internet is that both are viewed as basic necessities. During periods of economic turbulence, consumers are unlikely to cancel their access to the outside world. Wireless retail postpaid churn rate was only 1.12% during the fourth quarter, with average revenue per account climbing by 4.2% from the prior-year period. Consumers are sticking around, with the 5G revolution incenting a steady upgrade to wireless devices.
Though Verizon's growth heyday ended long ago, you wouldn't know it by homing in on the company's broadband operations. Total broadband connections grew to more than 12.3 million in 2024 (a 15% year-over-year increase), which has the potential to boost its operating cash flow. Best of all, broadband subscribers are more likely to bundle their services, which can improve customer loyalty and, ultimately, Verizon's operating margin.
The final thing to note about Verizon is that its financial flexibility is improving. Over the last two years, its total unsecured debt has declined by almost 10% to $117.9 billion. When coupled with a forward P/E ratio of around 8, Verizon stands out as an amazing deal.
Ford Motor Company: 6.51% yield
The third brand-name, ultra-high-yield dividend stock that patient investors can purchase with $300 right now is legacy automaker Ford Motor Company (NYSE: F). Excluding the COVID-19 crash in the first quarter of 2020, Ford's yield hasn't regularly parked above 6% since 2019.
Ford's yield topping 6% is a reflection of its stock touching a greater-than-four-year low this week. Steep losses from its electric vehicle (EV)-focused Model e segment in 2024, along with uncertainties that caused management to forecast a tough year in 2025 -- Ford's EBIT (earnings before interest and taxes) forecast of $7 billion to $8.5 billion for 2025 missed the mark -- led to a breakdown.
Despite the cyclical nature of legacy automakers, there are a handful of long-term catalysts investors can focus on. For example, Ford does have the luxury of adjusting its spending spigot to match consumer demand. Being mindful of tepid EV demand allows management to pare back spending and shift it to legacy segments that are generating healthy profits.
Ford's shareholders can also take solace in knowing the company is making strides to improve its production quality. While higher-than-anticipated warranty expenses have weighed on the company's profits in recent years, many of these issues can be traced to before Jim Farley became CEO in October 2020. In 2024, J.D. Power's "Initial Quality Study" put Ford in the top third of all brands examined in terms of fewest problems per 100 vehicles.
To round things out, Ford F-Series pickup has been the best-selling truck in the U.S. for the last 48 years, and the top-selling vehicle domestically (period!) over the last 43 years. While bigger isn't always better in the business world, trucks are statistically better than sedans at generating juicier vehicle margins for automakers. As long as Ford can maintain the popularity of its F-Series truck line, its forward P/E ratio of roughly 5.4 is a steal.
Should you invest $1,000 in Pfizer right now?
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
Learn more »
*Stock Advisor returns as of February 7, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
32 minutes ago
- Globe and Mail
Vaccine stocks muted as investors assess Kennedy's overhaul of key panel
Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S. Health Secretary Robert F. Kennedy Jr.'s surprising decision to fire all 17 members of a key expert panel late on Monday. Shares of U.S. vaccine maker Moderna (MRNA-Q) fell 2 per cent while Novavax (NVAX-Q) was down marginally. Merck (MRX-N) and Pfizer (PFE-N) rose between 1.4 per cent and 2 per cent. European shares of AstraZeneca (AZN-Q) closed slightly higher, while BioNTech (BNTX-Q) closed marginally lower. Analysts and investors said that while the unprecedented dismissals of all members of the Advisory Committee on Immunization Practices (ACIP) represented a risk for vaccine makers, the weak performance of those stocks in 2025 suggested that Kennedy's skepticism around vaccines was already factored in. Shares of most big drugmakers are down in 2025, compared with a 2-per-cent gain in the S&P 500 index. Since his appointment as health secretary under President Donald Trump, Kennedy has made several changes to reshape the regulation of vaccines, food and medicine. However, firing members of the ACIP remains his most far-reaching move yet. 'For vaccine makers, policy risk has already been cemented into share prices,' Morningstar analyst Karen Anderson said, even though the move was sudden and went against the promises that Kennedy made to Senator Bill Cassidy before his appointment was confirmed. Mr. Kennedy's decision comes less than three weeks before the next panel meeting, where the committee is slated to discuss recommendations for who should receive vaccines for diseases like respiratory syncytial virus, or RSV. 'It seems difficult to refill the panel with experts before the June 25th meeting,' said Jeff Jonas, portfolio manager at Gabelli Funds. 'But it's clearly going to be more difficult and more expensive to get future vaccines approved, and I'd expect to see less industry focus and effort here,' Jonas added, despite recent positive news such as the limited approval of Novavax's COVID shot and Merck's RSV therapy. Some analysts expressed concerns that the new committee members, who have not been named, might be more sympathetic to Mr. Kennedy's views on vaccines, an idea shared by scientific experts and doctors. Although the makeup of a reconstituted ACIP is yet to be determined, 'new members will likely be sympathetic to at least some of RFK's beliefs regarding alleged dangers of vaccines,' Leerink analyst Daina Graybosch wrote in a note. Ms. Graybosch said that the move could negatively impact approved vaccine recommendations and increase the burden of evidence and costs for future vaccine development. It is unclear when Mr. Kennedy will announce the new members, who the agency said are under consideration, or whether the agenda will follow the meeting description posted on the Federal Register on Monday. Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.


Toronto Star
an hour ago
- Toronto Star
Auditor general finds F-35 costs soar amid project delays, pilot shortages
OTTAWA - The estimated cost of Canada's incoming fleet of advanced stealth fighters exploded by nearly 50 per cent in just a few years, auditor general Karen Hogan said Tuesday in a new report. Federal Politics Ottawa repeatedly violated procurement rules in giving ArriveCan firm nearly $100M in contracts, auditor general finds Federal agencies failed to justify procurement methods, follow security measures and monitor the The fighter jet audit was one of eight tabled in the House of Commons by Hogan and environment commissioner Jerry DeMarco. The reports flag problematic procurement contracts, a backlog in applications for First Nations status and a delay in reducing the amount of federal office space. An investigation by the auditor general concluded that costs associated with the F-35 advanced fighter jet program are running $8.7 billion higher than the original estimates. ARTICLE CONTINUES BELOW And it warns the program is being plagued by delays and critical shortfalls — including a lack of qualified pilots. The report lands in the middle of an active review ordered by Prime Minister Mark Carney to examine possible alternatives to the F-35. He ordered the review in response to U.S. President Donald Trump's trade war with Canada. National Defence said in 2022 the base price for the F-35s would be $19 billion. Just two years later, the number has climbed to $27.7 billion. That estimate does not include figures for infrastructure upgrades or weapons. The report says the department's 2022 estimates relied on outdated data from 2019 — despite the availability of better estimates showing 'that costs of the aircraft had already increased substantially.' The audit says issues associated with the global pandemic — such as runaway inflation, rising costs for facilities and munitions and volatile foreign exchange rates — pushed the price tag sky high. Defence Minister David McGuinty's office sent out a written statement to media that blamed the increased costs on 'external economic conditions driven by the COVID-19 pandemic, including global supply chain disruptions, workforce shortages, and increased inflation and foreign exchange rates.' ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW 'In combination with increased global tensions and related impacts on the availability and demand for materials, we would not have been able to deliver the full scope of this project under our previous budget,' he said in the statement. Federal Politics Cost of F-35A fighter jet program has ballooned to more than $33B, auditor general finds Auditor General Karen Hogan published a new report that said the projected costs could be about But Hogan also warned Tuesday that the program faces 'significant risks that could jeopardize the timely introduction of the new fleet.' She said the department successfully identified the risks but has not planned appropriately to mitigate them. Construction of two new fighter squadron facilities — in Cold Lake, Alta., and Bagotville, Que. — is running three years behind schedule. The report says the facilities will not be ready until at least 2031 because the department needs to 'redo important elements' of their design. The department started planning the new facilities in 2020 before the government had settled on the F-35. The aircraft comes with significant infrastructure security requirements. 'Costs to develop an interim solution to support the new jets will further increase infrastructure expenses,' the report warned. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW It said the department produced a contingency plan to operate the aircraft from temporary facilities but the plan fell short because it was incomplete and offered 'no proposed actions nor a cost estimate.' Canada is also still short of qualified pilots to fly the advanced aircraft — despite being warned about this in 2018. The report said the F-35 program lacks measures to minimize potential risks and the department failed to produce robust contingency plans. It notes that the department identified cost overruns from inflation and currency fluctuations as potential risks to monitor, but plans to track those risks were never approved by officials. The Liberal government announced in 2017 it planned to purchase 88 new fighter jets. It signed a contract with Lockheed Martin for the F-35s in 2023. The modern jets are needed to replace Canada's aging CF-18 fleet, which is nearing the end of its service life. The fighter jets are expected to be delivered between 2026 and 2032. Over the next two years, the initial eight will be sent to a U.S. air force base in Arizona, where Canadian pilots will be trained to fly them. The rest will be delivered to Canada starting in 2028. ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW The report said the Joint Strike Fighter Program Office conducted various assessments that uncovered 'significant issues,' such as 'insufficient departmental engineering personnel to service support equipment for both the CF-18 Hornet and CF-35A during the transition.' The audit said that at the end of the last fiscal year in March, National Defence earmarked $935 million for the U.S. government for the first four jets and related items needed to produce another eight aircraft. It says about $197 million has been paid out already. On top of that, National Defence spent another $516 million on the project, including $270 million in infrastructure costs. This report by The Canadian Press was first published on June 10, 2025. Politics Headlines Newsletter Get the latest news and unmatched insights in your inbox every evening Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. Please enter a valid email address. Sign Up Yes, I'd also like to receive customized content suggestions and promotional messages from the Star. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Politics Headlines Newsletter You're signed up! You'll start getting Politics Headlines in your inbox soon. Want more of the latest from us? Sign up for more at our newsletter page.
Montreal Gazette
2 hours ago
- Montreal Gazette
‘Stable' Quebec avoids a second credit rating downgrade
Quebec News By QUEBEC — A second credit rating agency has taken a look at the Quebec government's finances and says it is comfortable with the province's debt situation. In a statement issued Tuesday, the Canadian agency DBRS decided to maintain Quebec's credit rating, which determines the costs of borrowing to finance the debt, at AA (low) with a 'stable perspective.' The DBRS decision is the opposite of the decision to lower Quebec's credit rating by another agency, Standard and Poor's, in April. S&P lowered Quebec's rating from AA- to A+. It was the first time in 30 years that Quebec suffered a credit downgrade. It came as a blow to Premier François Legault's government, which was first elected in 2018 promising sound fiscal management. 'Because or the ongoing tariff threat, Morningstar DBRS anticipates some near-term deterioration in Quebec's fiscal and debt metrics, potentially reducing flexibility within its current credit ratings,' DBRS said in a statement. 'However, the slowing pace of expenditure growth and continued commitment to restore fiscal balance, along with the province's large and diversified economy, give us comfort that Quebec can minimize the deterioration in its public finances. 'Despite the near term deterioration, the province remains committed to restoring fiscal balance by 2029-30, consistent with the goal articulated in last year's budget.' In his 2025-2026 budget presented March 25, Quebec Finance Minister Eric Girard forecast a $13.6-billion deficit, a historic record. The budget included an annual increase in spending of only 1.7 per cent but record spending on infrastructure projects as a way to counter the effects of an economic downturn sparked by American trade tariffs. S&P based its downgrade on the increase in government spending, including the infrastructure allocation. DBRS takes note of Quebec's approach but remains optimistic. 'As a result of near-term deterioration in the fiscal outlook and a substantial capital investment program, Quebec has relaxed its debt reduction targets. The province plans to reduce net debt to GDP to 35.5 per cent by 2032-33 and 32.5 per cent by 2037-38 (previously 33 per cent and 30 per cent respectively). The agency adds: 'While the ongoing trade uncertainty is expected to weigh on consumer and business confidence and investment intentions, domestic consumption should remain supported by easing monetary policy along with relatively strong labour markets and household savings.' Legault has said if Quebec is hit with full 25-per-cent tariffs on its trade, the province could lose 100,000 to 160,000 jobs.